Squarepoint
ITOS

Squarepoint’s iTeos Therapeutics ITOS Stock Holding History

Squarepoint’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,716
Closed -$328K – 5003
2024
Q4 		$328K Sell
42,716
-18,686
-30% -$161K ﹤0.01% 4085
2024
Q3 		$627K Buy
61,402
+41,766
+213% +$637K ﹤0.01% 2939
2024
Q2 		$291K Sell
19,636
-38,801
-66% -$556K ﹤0.01% 3447
2024
Q1 		$797K Sell
58,437
-42,362
-42% -$462K ﹤0.01% 2746
2023
Q4 		$1.1M Buy
100,799
+75,591
+300% +$749K ﹤0.01% 2453
2023
Q3 		$276K Buy
+25,208
New +$322K ﹤0.01% 3220
2023
Q2 		– Sell
-54,115
Closed -$737K – 3782
2023
Q1 		$737K Buy
+54,115
New +$970K ﹤0.01% 2087
2021
Q3 		– Sell
-23,504
Closed -$603K – 3157
2021
Q2 		$603K Buy
23,504
+15,141
+181% +$361K ﹤0.01% 2003
2021
Q1 		$286K Buy
+8,363
New +$302K ﹤0.01% 2442

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint's ITOS Position: Q1 2025 in Review

Squarepoint sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 42,716 shares — an estimated $328K sold.

Squarepoint first reported a position in ITOS in Q1 2021 and held it in 9 quarters. The position peaked at $1.1M in Q4 2023. 131 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

  • Squarepoint reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Squarepoint sold 42,716 iTeos Therapeutics shares in Q1 2025, an estimated $328K.
  • Squarepoint first reported a position in iTeos Therapeutics in Q1 2021 and held it in 9 quarters.
  • Squarepoint's iTeos Therapeutics position peaked at $1.1M in Q4 2023.
  • 131 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.